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402(p ¼ NS). There was no difference in reported adverse
events.
In conclusion, compared with conventional CA
guidance, FS alone was found to be an equally safe
and effective protocol, with similar immediate pro-
cedural and 6-month MACE rates, as well as similar
clinical outcomes for PCI, and had a signiﬁcantly
lower radiation at the source.Kamal H. Sharma, MD, DNB
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Diabetes and
Cardiovascular Risk
Reduction From High-Dose
Statin Therapy in Pre-Diabetics
and Non–Pre-DiabeticsAn Analysis From TNT and IDEALStatins reduce coronary and cerebrovascular events
in primary and secondary prevention. More intensive
statin therapy compared with moderate-intensity
statin therapy decreases risk even further (1).
Therefore, the 2013 American College of Cardiology/
American Heart Association (ACC/AHA) guidelines
recommend high-intensity statin therapy in high-
risk patients. This recommendation is partly on the
basis of the documented safety of higher doses.
However, meta-analyses have reported a slight
increase in the risk of new-onset diabetes (NOD)
with statin therapy over placebo; this risk in-
creases by an additional 12% with high-intensity
therapy (2).Fasting blood glucose (FBG) >100 mg/dl is a strong
predictor of NOD; however, the incidence of NOD
during statin therapy in patients with pre-diabetes
(PD), which is deﬁned as a FBG of 100 to 126 mg/dl,
compared with those with normal glucose levels, has
not been previously reported. We describe the inci-
dence of NOD in patients with and without PD at
baseline from the TNT (Treating to New Targets) and
IDEAL (Incremental Decrease in Clinical Endpoints
Through Aggressive Lipid Lowering) randomized
clinical trials.
We pooled patients without diabetes at baseline
from both the TNT and IDEAL trials (3,4). The TNT
study randomized 10,001 patients with documented
coronary heart disease to atorvastatin 10 or 80
mg/day and followed them for a median of 4.9 years
(3). The IDEAL study randomized 8,888 patients with
a previous myocardial infarction (MI) to simvastatin
20 to 40 mg/day or atorvastatin 80 mg/day with a
median follow-up of 4.8 years (4).
The primary endpoint of our analysis was the
composite of coronary heart disease death, nonfatal
MI, resuscitated cardiac arrest, and stroke. NOD was
deﬁned prospectively as at least 2 post-baseline FBG
measurements $126 mg/dl or at least 1 post-baseline
FBG $36 mg/dl above baseline (5). FBG was
measured at each 12-month visit in TNT and at
randomization and at the end of study in IDEAL. We
also included patients who had NOD identiﬁed
through adverse event reporting or patients who
received new concomitant diabetic medication.
Of the total 15,056 patients from both trials without
diabetes at baseline, 5,924 (39%) had PD, and 9,132
(71%) patients did not. PD and non-PD patients were
evenly balanced across the statin treatment arms.
Compared with those without PD, PD patients were
more likely to be older, to be men, to have metabolic
syndrome, to have higher baseline blood pressure,
and to have a history of hypertension. PD patients
also had, on average, a higher body mass index,
higher FBG, higher triglyceride levels, and lower
levels of high-density lipoprotein cholesterol.
During the mean 5-year follow-up, 14.2% of PD
patients developed NOD compared with 2.9% of pa-
tients without PD (hazard ratio [HR]: 5.29, 95%
conﬁdence interval [CI]: 4.6 to 6.1; p <0.001). As
shown in Figure 1, the incidence of NOD was not time-
dependent, and occurred at the same rate throughout
the trial. In patients with PD, the risk of NOD was
higher in the high-intensity statin group (HR: 1.20,
95% CI: 1.04 to 1.37; p ¼ 0.010). In patients without
PD, the difference between the high- and moderate-
intensity treatment groups was not statistically
signiﬁcant (HR: 1.08, 95% CI: 0.85 to 1.38; p ¼ 0.527).
FIGURE 1 Effect of Pre-Diabetes on Incidence of New-Onset Diabetes
0.20
0.15
Treatment HR (95% CI) = 1.20 (1.04 to 1.37) p=0.010 (Pre-Diabetic)
Treatment HR (95% CI) = 1.08 (0.85 to 1.38) p=0.527 (Not Pre-Diabetic)
0.10
0.05
0.00
0 1 2
Time From Randomization to New-Onset Diabetes (Years)
Pr
ob
ab
ili
ty
 o
f N
ew
-O
ns
et
 D
ia
be
te
s
3 4 5
Atorva 80 mg (Pre-Diabetic)
Atorva 80 mg (Not Pre-Diabetic)
Atorva 10 mg/Simva 20-40 mg (Pre-Diabetic)
Atorva 10 mg/Simva 20-40 mg (Not Pre-Diabetic)
Kaplan-Meier event-free survival curves from the TNT and IDEAL trials showing new-onset diabetes (NOD) in pre-diabetics and non–pre-
diabetics by treatment group. IDEAL ¼ Incremental Decrease in Clinical Endpoints Through Aggressive Lipid Lowering; TNT ¼ Treating to
New Targets.
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403The primary composite endpoint was greater for
the PD group compared with the non-PD group (10.5%
and 9.6%, respectively; HR: 1.11, 95% CI: 1.00 to 1.23,
p ¼ 0.05). High-intensity statin treatment compared
with moderate-intensity statin treatment reduced
cardiovascular events in patients with PD (9.5% vs.
11.5%; HR: 0.82, 95% CI: 0.70 to 0.96; p ¼ 0.014) and
without PD (8.9% vs. 10.2%; HR: 0.87, 95% CI: 0.76 to
0.99; p ¼ 0.038).
In summary, in this analysis of 2 large cohorts of
patients without diabetes who were taking statins, PD
was a very strong predictor of the development of NOD
during the 5-year follow-up, with high-intensity statin
therapy, compared with moderate-intensity statin
therapy, signiﬁcantly increasing the risk of NOD in the
PD group, but not in the non-PD group. In contrast, the
risk of cardiovascular events was only marginally
greater in the PD group compared with the non-PD
group, and high-intensity statin therapy compared
with moderate-intensity statin therapy signiﬁcantly
reduced cardiovascular events in both groups.Payal Kohli, MD
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With a New Delivery
Device for LAA Ligation
Among Various U.S. CentersThe Lariat suture delivery device (SentreHeart,
Redwood City, California) has been used to exclude
the left atrial appendage (LAA). Thus far, there have
not been any randomized controlled trials or large
multicenter experiences reported on the device.
Price et al. made an attempt to describe their
multicenter experience with the Lariat device as
part of the U.S. Transcatheter LAA Ligation Con-
sortium on the safety and efﬁcacy of transcatheter
ligation of the LAA for stroke prevention in atrial
ﬁbrillation (1).
It is an important study that showed how a proce-
dure could have suboptimal outcomes if not executed
properly. In addition, it was fraught with several is-
sues that deserve attention and were not discussed
in the accompanying editorial. Their sample size re-
ﬂected a small portion (7.7%) of the 2,000-plus cases
that were performed in the country at the time of this
publication. Their experience might not be a reﬂec-
tion of the performance of this device across other
centers that have more experience. The majority of
the participant institutions seemed to have limited
experience with this device (mean of 19 cases per
institution). There was no mention of the selection
criteria for the participating centers and the experi-
ence and training of the operators, and the exclusion
and inclusion criteria were not deﬁned. It is not clear
what percentage of these patients underwent the
procedure on a compassionate basis (outside of
standard eligibility as recommended by the manu-
facturer and mentioned in other studies) (2,3). This
muticenter experience is far from being a true
consortium.
The bleeding and major complication rates re-
ported by the investigators are concerning, but these
rates do not reﬂect the clinical experience of other
operators in the country from single-center experi-
ences (3,4). In a quick survey, conducted in 11 U.S.
sites (6 academic centers and 5 community-based
practices with a mean 40 patients per institution)
that included 441 patients, acute closure was seen
in 420 patients (95%); an incidence of bleeding of>500 ml was seen in 10 patients (2.2%); 9 patients
(2%) needed blood transfusions; and 6 patients
(1.3%) needed open heart surgery for cardiac per-
foration. Most of these complications were seen
early on, during the use of a 18-gauge Pajunk nee-
dle (Pajunk Medical Systems, Norcross, Georgia) for
pericardial access. Subsequently, operators switched
to a micropuncture needle in a total of 231 (52.3%)
patients. There were no complications related to
pericardial access. Three hundred sixty-three pa-
tients (82.3%) underwent follow-up transesophageal
echocardiographies, with 32 patients (7.2%) showing
a leak during follow-up transesophageal echocardi-
ography at >1 mm. Eight patients (2%) had delayed
thrombus formation at the ligation site. Five pa-
tients (1.1%) had delayed pericardial effusion, and 9
patients (2%) had delayed pleural effusions. No
deaths were noted in any of these patients. It
should also be noted that the initial results from 1
of the participating centers in the U.S. Transcatheter
LAA Ligation Consortium reported their experience,
which was vastly different from the recent registry.
This discrepancy suggests the wide variation in
adherence to the procedure as previously described
(2,5), patient selection, and evolution of the tech-
nique. In addition, the investigators mentioned the
use of a micropunture needle for pericardial access
but did not indicate the percentage of patients in
which this needle was used. From our survey, the
incidence of using the micropuncture needle for
pericardial access was in 52.3%, with no evidence of
bleeding or any other major complications.
Given the limitations noted from the accompa-
nying editorial and the contrary experience of the
surveyed centers, the results of this study should
be evaluated with caution, because these ﬁndings
might not be reﬂective of the global safety and
effectiveness proﬁle of the Lariat procedure in expe-
rienced hands for appropriately selected patients. A
prospective, rigorous clinical investigation is required
to prove the risk and/or beneﬁt proﬁle of this therapy,
which will be forthcoming in the near future.*Abdi Rasekh, MD
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